STOCK TITAN

Natera Inc - NTRA STOCK NEWS

Welcome to our dedicated page for Natera news (Ticker: NTRA), a resource for investors and traders seeking the latest updates and insights on Natera stock.

Overview of Natera Inc

Natera Inc (symbol: NTRA) is a San Carlos, California-based diagnostic and research company that integrates advanced NIPT, bioinformatic, and molecular diagnostic technologies to improve genetic and genomic testing. Leveraging breakthroughs from the human genome project, the company specializes in non-invasive prenatal testing, preimplantation genetic diagnosis, and advanced oncology diagnostics. By employing sophisticated proprietary algorithms, Natera delivers high accuracy and reliability across a spectrum of tests, ensuring couples and patients receive critical genetic insights at every stage of care.

Core Services and Product Categories

Natera has developed a comprehensive portfolio of tests that address various healthcare challenges:

  • Non-Invasive Prenatal Testing (NIPT): Utilizing a simple blood draw from the mother, Natera’s Panorama test offers in-depth chromosomal screening, enabling early detection of genetic conditions with minimum risk during pregnancy.
  • Carrier Screening: Through Horizon Carrier Screening, the company assesses carrier status for numerous genetic conditions, helping prospective parents understand and manage risks associated with severe genetic diseases.
  • Oncology Diagnostics: The Signatera test is designed for molecular residual disease assessment in cancer patients, providing clinicians a tool to detect circulating tumor DNA and monitor treatment effectiveness post-therapy.
  • Transplant Rejection Assessment: The Prospera test assists in monitoring organ transplant recipients by evaluating rejection risk, thereby supporting post-transplant care management.

Technological Innovation and Expertise

Natera’s edge in the competitive diagnostic landscape lies in its pioneering use of bioinformatic algorithms and molecular science. The integration of advanced computing with genetic analysis allows the company to transform raw genomic data into actionable clinical insights. This is particularly significant in the fields of prenatal and oncology testing, where early and accurate diagnosis can have lasting impacts on patient management and treatment decisions. The company continuously applies insights from the latest genomic research to refine and expand its testing services.

Market Position and Industry Significance

Within the diagnostic and genetic testing space, Natera distinguishes itself through its commitment to precision and reliability. The firm occupies a unique niche where technological innovation meets clinical application, serving diverse patient groups including expectant couples, individuals undergoing fertility treatments, cancer survivors, and organ transplant recipients. Its tests are designed for use in specialized clinical settings, further emphasizing the role of expert genetic counseling and technical support in achieving accurate results. This multidimensional approach not only enhances patient care but also supports broader efforts in personalized medicine and informed clinical decision-making.

Integration of Molecular Diagnostics and Genomic Informatics

The success of Natera’s offerings is rooted in its detailed understanding of genomic data and its translation into diagnostic solutions. The company applies rigorous scientific methods and robust bioinformatic systems to parse complex genomic information and deliver clear, actionable reports. This disciplined approach not only builds trust with healthcare providers and patients alike but also sets a high standard for the industry by ensuring that every result is backed by proven science and extensive expertise.

Commitment to Informed Clinical Decisions

From conception to ongoing health management, Natera’s testing methodologies empower clinicians and patients with essential genetic insights. The company emphasizes informed decision-making by combining advanced technology with comprehensive genetic counseling. This ensures that testing results are interpreted accurately and contextualized within each patient’s unique clinical profile, supporting better outcomes and safer health journeys.

Understanding Natera in the Competitive Landscape

In a market that is increasingly reliant on precision diagnostics, Natera stands out by focusing on the reliability and depth of its genetic tests. Although competitive pressures exist from other diagnostic firms, Natera’s unique blend of molecular diagnostics and bioinformatics uniquely positions it to address complex genetic challenges across multiple conditions. The company’s detailed-oriented approach and commitment to scientifically validated testing procedures underline its reputation among healthcare professionals and investors aiming to understand the nuances of genetic diagnostics.

Rhea-AI Summary
Natera, Inc. (NTRA) progresses in patent infringement litigation against CareDx with a $96.3 million jury verdict in lost profits and past royalties. The U.S. District Court will decide on future royalties for ongoing AlloSure testing. Discovery and briefing to continue till summer 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.66%
Tags
none
-
Rhea-AI Summary
Natera, Inc. (NTRA) announces that its Signatera MRD test has met coverage requirements from CMS in new indications for ovarian and breast cancer. The test has shown promising results in detecting recurrence early and predicting therapy response, potentially improving outcomes for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.29%
Tags
none
-
Rhea-AI Summary
Natera, Inc. (NTRA) to release Q4 and year-end 2023 financial results on Feb. 28, 2024. Conference call and webcast to follow. Details provided for investors and traders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.57%
Tags
Rhea-AI Summary
Natera, Inc. (NASDAQ: NTRA) announced a study validating its MRD test, Signatera, in endometrial cancer. The study showed that patients who tested Signatera MRD-positive experienced significantly higher rates of recurrence, making Signatera a powerful post-surgical biomarker of recurrence risk for patients with endometrial cancer. The potential for Signatera to redefine adjuvant treatment pathways in endometrial cancer was demonstrated in the study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.61%
Tags
none
-
Rhea-AI Summary
Natera, Inc. (NTRA) announced a new study demonstrating the effectiveness of its Signatera MRD test in detecting recurrence early in patients with resected stage I-II non-small cell lung cancer. The study showed that clinical management was altered in 100% of patients with a Signatera positive result, highlighting the potential of this test in risk stratification. With NSCLC accounting for 81% of all lung cancer diagnoses in the U.S., this study has significant implications for patient care and cancer management.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.62%
Tags
none
-
Rhea-AI Summary
Natera, Inc. (NTRA) has won a patent infringement case against CareDx, Inc., with the jury awarding Natera $83.7 million in lost profits and $12.6 million in past royalties. The jury also found that all asserted claims of Natera's patents are valid and provided an advisory verdict that all asserted claims are valid under 35 U.S.C. Sec. 101. Further proceedings will determine whether CareDx's future sales of new versions of AlloSeq and AlloSure also infringe Natera's patents.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.48%
Tags
none
Rhea-AI Summary
CareDx, Inc. (Nasdaq: CDNA) has been found to have not infringed on Natera, Inc.'s patent 10,655,180 but was found to have infringed on patent 11,111,544. The District of Delaware jury awarded Natera damages of $83,679,521 in lost profits and $12,535,500 in past royalties for alleged infringement by AlloSure from September 2021 through August 2023. CareDx intends to seek judicial review of the verdict. The decision does not impact patient or physician access to CareDx's current offerings, including AlloSure or AlloMap.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.48%
Tags
none
-
Rhea-AI Summary
Natera, Inc. (NASDAQ: NTRA) announced the publication of two new studies in Nature Medicine evaluating Natera’s personalized and tumor-informed molecular residual disease (MRD) test, Signatera.™ The first study, AMPLIFY-201, evaluated the ELI-002 cancer vaccine and enrolled 25 patients with solid tumors. Results showed that 21 patients had Signatera-positive status after locoregional treatment, and tumor biomarker responses were observed in 84% of patients. The study highlights the potential utility of ctDNA as a reliable surrogate biomarker for treatment efficacy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.51%
Tags
none
-
Rhea-AI Summary
Natera, Inc. (NTRA) has acquired certain assets from Invitae (NVTA) related to non-invasive prenatal screening and carrier screening business. The upfront payment to Invitae was $10 million, with potential milestone payments totaling $42.5 million. Invitae will transition its customers to Natera. Natera CEO, Steve Chapman, expressed commitment to providing excellent service and supporting additional patients and providers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.08%
Tags
Rhea-AI Summary
Invitae (NVTA) completes the sale of reproductive health assets to Natera (NTRA) for up to $52.5 million, aiming to focus on clinical germline genetic information and reduce operating expenses by approximately $44 million annually. Natera has hired Invitae reproductive health sales representatives and will take over customer transition for non-invasive prenatal and carrier screening.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.08%
Tags
none

FAQ

What is the current stock price of Natera (NTRA)?

The current stock price of Natera (NTRA) is $133.831 as of April 4, 2025.

What is the market cap of Natera (NTRA)?

The market cap of Natera (NTRA) is approximately 17.8B.

What core services does Natera Inc offer?

Natera Inc offers a suite of genetic testing services, including non-invasive prenatal testing, carrier screening, oncology diagnostics, and transplant rejection assessments. Each service is supported by advanced bioinformatic algorithms and molecular technologies.

How does Natera ensure accuracy in its testing processes?

Natera leverages proprietary bioinformatic algorithms and rigorous scientific methods to process complex genomic data. This technology-driven approach underpins the accuracy and reliability of its prenatal, oncology, and other genetic tests.

What is non-invasive prenatal testing (NIPT) and how does Natera apply it?

Non-invasive prenatal testing (NIPT) involves screening for genetic abnormalities through a simple maternal blood draw. Natera’s Panorama test applies this technique to provide early genetic insights and reduce risks associated with invasive testing methods.

What role does bioinformatics play in Natera's diagnostic solutions?

Bioinformatics is central to Natera’s approach, converting raw genomic data into clinically actionable insights. The integration of computing with molecular diagnostics allows the company to deliver detailed, accurate results across its testing portfolio.

How does Natera address the needs of oncology patients?

Through its Signatera test, Natera detects circulating tumor DNA to monitor molecular residual disease in cancer patients. This aids in evaluating treatment effectiveness and detecting potential recurrence, thereby supporting informed clinical decisions.

In what ways does Natera contribute to the field of genetic diagnostics?

Natera is at the forefront of advancing genetic diagnostics by integrating cutting-edge molecular science with innovative bioinformatic techniques. This combination ensures highly accurate testing in prenatal, reproductive, and oncology settings.

How is Natera positioned within the competitive landscape of diagnostic companies?

Natera distinguishes itself by focusing on precise, scientifically validated testing and comprehensive genetic counseling services. While facing competition from similar diagnostic firms, its unique blend of technology and expertise sets it apart in specialized clinical applications.
Natera Inc

Nasdaq:NTRA

NTRA Rankings

NTRA Stock Data

17.78B
130.00M
3.45%
93.67%
2.13%
Diagnostics & Research
Services-medical Laboratories
Link
United States
AUSTIN